Neurotrope, Inc.·4

Nov 17, 3:32 PM ET

Neurotrope, Inc. 4

4 · Neurotrope, Inc. · Filed Nov 17, 2015

Insider Transaction Report

Form 4
Period: 2015-11-13
Freiman Paul E.
DirectorSee Remarks
Transactions
  • Purchase

    Series D Warrant

    2015-11-13+166,667166,667 total(indirect: By Trust)
    Exercise: $1.00Common Stock (166,667 underlying)
  • Purchase

    Series C Warrant

    2015-11-13+166,667166,667 total(indirect: By Trust)
    Exercise: $1.25Exp: 2020-11-13Common Stock (166,667 underlying)
  • Purchase

    Series B Preferred Stock

    2015-11-13+1,666.67166,667 total(indirect: By Trust)
    Exercise: $0.00Common Stock (166,667 underlying)
  • Purchase

    Series B Warrant

    2015-11-13+166,667166,667 total(indirect: By Trust)
    Exercise: $0.80Exp: 2020-11-13Common Stock (166,667 underlying)
  • Purchase

    Series E Warrant

    2015-11-13+166,667166,667 total(indirect: By Trust)
    Exercise: $1.50Common Stock (166,667 underlying)
  • Purchase

    Series A Warrant

    2015-11-13+166,667166,667 total(indirect: By Trust)
    Exercise: $0.80Exp: 2020-11-13Common Stock (166,667 underlying)
Footnotes (7)
  • [F1]The reported securities are included within units with a purchase price of $0.60 per unit, each unit consisting of one one-hundredth of a share of Series B Preferred Stock, one Series A Warrant, one Series B Warrant, one Series C Warrant, one Series D Warrant and one Series E Warrant.
  • [F2]The Series B Preferred Stock may be converted at any time by the holder at an initial conversion ratio of one share of Common Stock per one one-hundredth share of Series B Preferred Stock and have no expiration date.
  • [F3]Each Series A Warrant allows the reporting person to acquire, at an exercise price of $0.80 per share with an expiration date five years from the date of issuance, one share of Common Stock subject to adjustment.
  • [F4]Each Series B Warrant allows the reporting person to acquire, at an exercise price of $0.80 per share with an expiration date of one year from the date of issuance, one share of Common Stock subject to adjustment.
  • [F5]Each Series C Warrant allows the reporting person to acquire, at an exercise price of $1.25 per share with an expiration date of five years from the date of issuance, one share of Common Stock subject to adjustment.
  • [F6]Each Series D Warrant will be exercisable only if and to the extent that the Series B Warrants are exercised and will expire on the five year anniversary of the date that the Series B Warrant is initially exercised.
  • [F7]Each Series E Warrant will be exercisable only if and to the extent that the Series C Warrants are exercised and will expire on the five year anniversary of the date that the Series C Warrant is initially exercised.

Documents

1 file
  • 4
    v424992_4.xmlPrimary

    OWNERSHIP DOCUMENT